BriaCell Therapeutics announced the opening of a new clinical site in Florida and the appointment of Dr. Elizabeth Tan-Chiu as the clinical site’s principal investigator.
BriaCell Therapeutics (TSXV:BCT; OTCQB:BCTXF) announced the opening of a new clinical site in Florida and the appointment of Dr. Elizabeth Tan-Chiu as the clinical site’s principal investigator, both will work to develop the company’s ongoing advanced breast cancer clinical trial.
As quoted in the press release:
Dr. Tan-Chiu will work closely with Cancer Insight, LLC., BriaCell’s contract research organization, to manage the clinical and regulatory aspects of the clinical trial on behalf of BriaCell.
“We are impressed with Dr. Tan-Chiu’s credentials and her profound knowledge and experiences in the management of breast cancer clinical trials, and we are grateful to have her as a principal investigator for the Phase I/IIa clinical trial of BriaVax™, our lead vaccine candidate for management of advanced breast cancer,” stated Dr. William Williams, President & CEO of BriaCell. “We are committed to excellence in patient care, and we are delighted to have Florida Cancer Care, which is known for outstanding cancer care, as our second site for the clinical trials of BriaVax™. We expect that the addition of Florida Cancer Care will provide availability to the vaccine for patients in the eastern regions of the US and speed up the process of patient enrollment in our ongoing clinical trial with BriaVax™.”